Search Results for “Johnson ” – Page 32 – media

J&J signs 15 deals for new healthcare solutions

Johnson & Johnson (J&J) has signed 15 new partnerships to explore, develop and advance new medical devices, therapeutics and consumer health solutions.
- Source: Verdict Medical Devices
- 706
- January 9, 2018
AI cancer Company Insight Johnson & Johnson
Scholar Rock scoops $47M to trial SMA drug

Scholar Rock has raised $47 million to take its treatment for spinal muscular atrophy (SMA) into the clinic. The series C tees up Scholar Rock to find out whether its myostatin blocker can best the underwhelming performance of one-time rivals from companies including Novartis.
- Source: fiercebiotech
- 494
- January 4, 2018
blocker Company Insight myostatin SMA
Researchers find potential path to repair multiple sclerosis-damaged nerves

Gene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases. For multiple sclerosis, specifically, increasing cholesterol synthesis gene expression in astrocytes of the spinal cord can be a pathway to repair nerves that affect walking.
- Source: medicalxpress
- 457
- December 27, 2017
multiple sclerosis neurological Researches
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Biotech, Inc. (Janssen) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC). Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC.
- Source: Janssen
- 489
- December 25, 2017
CRPC inhibitor New Approvals
U.S. FDA approves new diabetes drug from Merck and Pfizer

A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration(FDA) said, adding another competitor to a growing class of treatments.
- Source: Reuters
- 685
- December 25, 2017
ertugliflozin Merk New Approvals Pfizer
Bayer’s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease

The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS study
- Source: press.bayer
- 611
- December 15, 2017
Bayer CAD/PAD Company Insight Janssen rivaroxaban
LSP closes $330M medtech fund, plots 15 investments

LSP has raised $330 million for its second medical technology fund. The big jump in size over the first fund tees up LSP to place bets on 15 companies with close-to-market devices, diagnostics and digital health tools.
- Source: fiercebiotech
- 684
- December 14, 2017
Company Insight diagnostics digital health
Ddu College–China’s Import and Export Market Report of Antiallergic Drugs

Allergies, also known as allergic diseases, are a number of conditions caused by hypersensitivity of the immune system to something in the environment that usually causes little or no problems to most people. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma and anaphylaxis. Symptoms may include red eyes, an itchy rash, sneezing and a runny nose, shortness of breath or swelling. Food intolerances and food poisoning are separate conditions.
- Source: Ddu
- 5,898
- December 1, 2017
Allergies antiallergic drugs hypersensitivity Market Reports
Pfizer and Genentech Duke it Out in Court Over Herceptin Biosimilar Patents

On Friday, November 17, Genentech, a Roche company, sued Pfizer in a federal court in Wilmington, Delaware, over Pfizer’s biosimilar for Genentech’s Herceptin. Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Genentech also is demanding compensation for lost sales if Pfizer launches its copycat version before the Herceptin patents expire.
- Source: Biospace
- 644
- November 24, 2017
biosimilar Company Insight FDA Genentech herceptin Pfizer Roche
Study shows how gut bacteria may trigger MS

Alterations in gut bacteria at a young age could help to trigger and progress multiple sclerosis in people who are genetically predisposed to the autoimmune disease.
- Source: medicalnewstoday
- 495
- November 22, 2017
multiple sclerosis Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.